Search

Your search keyword '"Angelico, M."' showing total 1,251 results

Search Constraints

Start Over You searched for: Author "Angelico, M." Remove constraint Author: "Angelico, M."
1,251 results on '"Angelico, M."'

Search Results

2. Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation

3. Temporal trends of waitlistings for liver transplantation in Italy: The ECALITA (Evolution of IndiCAtion in LIver transplantation in ITAly) registry study

4. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

5. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study

6. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro

7. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

8. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

9. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation

10. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

11. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

12. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

13. Outcomes of Liver Transplant for Adults With Wilson’s Disease

14. Serum lipids and gallstone disease

19. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

20. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

21. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

22. How many bird and mammal extinctions has recent conservation action prevented?

23. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

24. How many bird and mammal extinctions has recent conservation action prevented?

27. Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study

30. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

31. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

32. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

33. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

34. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

35. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

36. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

37. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial

41. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

42. Worse Graft Survival in HCV-Infected Transplanted Females Receiving a Male Donor Graft. The Liver Match Study.: Abstract# O-164

45. Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

46. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

47. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

49. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

Catalog

Books, media, physical & digital resources